J&J Seeks Approval for Darzalex in Expanded Patient Group

With the sBLA filing, J&J is looking for approval of Darzalex in combination with the standard of care treatment regimen — Celgene’s CELG Revlimid (lenalidomide) and dexamethasone (Rd) — in patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).